U.S. markets closed
  • S&P Futures

    4,015.75
    +14.50 (+0.36%)
     
  • Dow Futures

    32,546.00
    +112.00 (+0.35%)
     
  • Nasdaq Futures

    12,923.25
    +33.00 (+0.26%)
     
  • Russell 2000 Futures

    1,757.60
    +9.90 (+0.57%)
     
  • Crude Oil

    69.45
    +0.19 (+0.27%)
     
  • Gold

    1,979.20
    -4.60 (-0.23%)
     
  • Silver

    23.31
    -0.03 (-0.12%)
     
  • EUR/USD

    1.0770
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    3.3800
    -0.0260 (-0.76%)
     
  • Vix

    21.74
    -0.87 (-3.85%)
     
  • GBP/USD

    1.2235
    +0.0005 (+0.04%)
     
  • USD/JPY

    130.8630
    +0.1620 (+0.12%)
     
  • Bitcoin USD

    27,877.10
    +268.96 (+0.97%)
     
  • CMC Crypto 200

    607.22
    -11.17 (-1.81%)
     
  • FTSE 100

    7,405.45
    -94.15 (-1.26%)
     
  • Nikkei 225

    27,425.80
    +40.55 (+0.15%)
     

Biohaven, Pfizer enter up to $1.24 billion deal to market migraine drugs

Nov 9 (Reuters) - Pfizer Inc will acquire overseas marketing rights to two migraine drugs from Biohaven Pharmaceutical Holding Co, for an upfront payment of $500 million and up to an additional $740 million in milestones, the companies said on Tuesday.

The upfront payment for rights to Biohaven's rimegepant and zavegepant includes $150 million cash and $350 million in the purchase of Biohaven equity at a 25% market premium, the drugmakers said. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Krishna Chandra Eluri)